Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer

By LabMedica International staff writers
Posted on 08 Jun 2026

Natera, Inc. More...

(Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating tumor DNA (ctDNA) from clinical trial samples collected in CytoDyn’s CLOVER Phase 2 study. The trial is assessing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, for patients with previously treated mCRC in combination with trifluridine/tipiracil (TAS-102) and bevacizumab.

The collaboration centers on Signatera, Natera’s personalized assay for detection of molecular residual disease (MRD). Signatera will be used to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment. Natera will also deliver customized real-world data (RWD) analyses using its proprietary oncology database, described as the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records.

Natera develops cell-free DNA–based testing and precision medicine tools across oncology, women’s health, and organ health, with its molecular diagnostics portfolio supported by more than 400 peer-reviewed publications. CytoDyn is a clinical-stage oncology company advancing leronlimab, a humanized monoclonal antibody that targets the CCR5 receptor, an immune system regulator implicated in cancer as well as infectious and autoimmune diseases.

By integrating MRD testing results with curated electronic medical record (EMR) data, the multimodal dataset enables analyses of patient populations, treatment patterns, ctDNA response rates, and response dynamics across diverse clinical settings. These analyses are expected to generate insights into molecular response and disease progression. The effort aims to inform future clinical development of leronlimab, including study design, biomarker-driven patient selection strategies, and translational research.

The collaboration follows completion of enrollment in the CLOVER study. It is also expected to complement ongoing translational and biomarker analyses from the trial that are aimed at further characterizing treatment response and informing subsequent development strategies. The companies indicated that the combined approach of longitudinal MRD assessment and linked clinical data is intended to provide real-world molecular insights specific to mCRC.

“Signatera has become an increasingly important tool in precision oncology and clinical development,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn. “Through this collaboration, we expect to gain valuable insights into ctDNA response kinetics and disease progression that may help guide future development strategies for leronlimab in colorectal cancer and potentially other solid tumor indications.”

“We are pleased to partner with CytoDyn and provide their team with insights derived from one of the largest and most comprehensive real-world molecular oncology data platforms,” said Matt Love, vice president, biopharma data & AI partnering, Natera. “Our platform enables biopharma partners to better understand disease biology, treatment response, and patient outcomes, helping inform key development decisions throughout the drug development lifecycle.”

Related Links
Natera
CytoDyn
 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.